What drove the 19.61% rise in 4881.T stock today?

The jump in 4881.T stock on 17 Mar 2026 was driven by heavy volume and renewed focus on Phase II clinical catalysts. Short-covering and a move above the 50-day average also supported buying. Check company releases for formal trial updates.

How does Meyka AI view 4881.T stock from a risk-reward lens?

Meyka AI grades 4881.T a **B (67.29)** with a HOLD bias. The model highlights high cash per share but negative EPS and trial risk. A positive clinical readout is the main upside catalyst; failed results would likely compress value.

What is the Meyka AI price forecast and implied change for 4881.T stock?

Meyka AI's yearly forecast for 4881.T stock is **JPY 50.53**, versus a current close of **JPY 122.00**, implying a model-based downside of **-58.56%**. Forecasts are model projections and not guarantees.

JP Stocks

FunPep (4881.T) up 19.61% to JPY 122 JPX close 17 Mar 2026: Phase II catalysts

ByHuzaifa Zahoor March 17, 2026March 17, 2026

4881.T stock led Japan’s small-cap gainers at market close on 17 Mar 2026, rising 19.61% to JPY 122.00 on the JPX. The move came on heavy turnover of 5,624,300.00 shares versus an average of 1,770,821.00, a relative volume of 3.64. Investors priced in clinical-stage updates and short-covering after a fresh run above the 50-day average of JPY 91.40. We examine the drivers behind today’s jump, the financial profile, technical signals, Meyka AI grade and a forecast comparison to highlight where risk and opportunity sit for FunPep Company Limited (4881.T)